Mavyret vs Paxlovid
A side-by-side look at two antiviral medications advertised on TV. Informational only — not medical advice.
| US Mavyret | US Paxlovid | |
|---|---|---|
| Generic name | glecaprevir/pibrentasvir | nirmatrelvir/ritonavir |
| Drug class | Direct-Acting Antiviral Combination | Antiviral Protease Inhibitor Combination |
| Treats | Hepatitis C | COVID-19 (mild to moderate) |
| Category | Antiviral | Antiviral |
| Manufacturer | AbbVie | Pfizer |
| Year approved | 2017 | 2023 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | $80M | $60M |
| Common side effects | Headache, Fatigue, Nausea, Risk of hepatitis B reactivation | Altered taste, Diarrhea, High blood pressure, Muscle aches |
Frequently asked questions
Is Mavyret or Paxlovid better?
Neither is universally "better." Mavyret (glecaprevir/pibrentasvir) and Paxlovid (nirmatrelvir/ritonavir) are both used for antiviral, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Mavyret and Paxlovid?
Mavyret is a Direct-Acting Antiviral Combination made by AbbVie, while Paxlovid is a Antiviral Protease Inhibitor Combination made by Pfizer. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Mavyret has the larger estimated TV advertising budget of the two.